0001193125-20-014823.txt : 20200127 0001193125-20-014823.hdr.sgml : 20200127 20200127080049 ACCESSION NUMBER: 0001193125-20-014823 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200127 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200127 DATE AS OF CHANGE: 20200127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allergan plc CENTRAL INDEX KEY: 0001578845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36867 FILM NUMBER: 20547120 BUSINESS ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 BUSINESS PHONE: (216) 523-5000 MAIL ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 FORMER COMPANY: FORMER CONFORMED NAME: Actavis plc DATE OF NAME CHANGE: 20130930 FORMER COMPANY: FORMER CONFORMED NAME: Actavis Ltd DATE OF NAME CHANGE: 20130607 8-K 1 d875269d8k.htm FORM 8-K Form 8-K
false 0001578845 0001578845 2020-01-27 2020-01-27 0001578845 us-gaap:CommonStockMember 2020-01-27 2020-01-27 0001578845 agn:FloatingRateNotesDue2020Member 2020-01-27 2020-01-27 0001578845 agn:M0.500NotesDue2021Member 2020-01-27 2020-01-27 0001578845 agn:M1.500NotesDue2023Member 2020-01-27 2020-01-27 0001578845 agn:M1.250NotesDue2024Member 2020-01-27 2020-01-27 0001578845 agn:M2.625NotesDue2028Member 2020-01-27 2020-01-27 0001578845 agn:M2.125NotesDue2029Member 2020-01-27 2020-01-27

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): Jan uary 27, 2020 (January 27, 2020)

 

ALLERGAN PLC

(Exact name of Registrant as specified in its charter)

 

Ireland

  

001-36867

  

98-1114402

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

Clonshaugh Business and Technology Park

Coolock, Dublin, D17 E400, Ireland

(Address of principal executive offices)

(862) 261-7000

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Ordinary Share, par value $0.0001 per share

  

AGN

  

New York Stock Exchange

Floating rate notes due 2020

  

AGN20A

  

New York Stock Exchange

0.500% notes due 2021

  

AGN21

  

New York Stock Exchange

1.500% notes due 2023

  

AGN23A

  

New York Stock Exchange

1.250% notes due 2024

  

AGN24A

  

New York Stock Exchange

2.625% notes due 2028

  

AGN28

  

New York Stock Exchange

2.125% notes due 2029

  

AGN29

  

New York Stock Exchange

 

 

Item 8.01. Other Matters.

On January 27, 2020, Allergan plc (“Allergan”) and AbbVie Inc. (“AbbVie”) announced that Allergan had entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase) (together, the “Divestitures”) in order to satisfy regulatory requirements in connection with the previously announced transaction whereby Venice Subsidiary LLC, a Delaware limited liability company and a direct wholly-owned subsidiary of AbbVie, will acquire Allergan (the “Transaction”) pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”) and a capital reduction under Sections 84 to 86 of the Act.

AstraZeneca plc will acquire brazikumab, an investigational IL-23 inhibitor in Phase 2b/3 development for Crohn’s Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

Nestlé S.A. (“Nestlé”) will acquire and take full operational ownership of Zenpep upon closing the transaction with customary transition support from Allergan. Zenpep is a treatment, which is available in the United States, for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. Nestlé also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.

The closings of the Divestitures are contingent upon receipt of U.S. Federal Trade Commission and European Commission approval, the closing of the Transaction, and the satisfaction of other customary closing conditions.

A copy of the press release relating to the announcement of the Divestitures is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.

   

Description

         
 

99.1

   

Press Release, dated January 27, 2020

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document)

FORWARD-LOOKING STATEMENTS

This report contains certain forward-looking statements, including with respect to the pending acquisition involving AbbVie and Allergan, Allergan’s divestitures of brazikumab and Zenpep and AbbVie’s, Allergan’s and/or the combined group’s estimated or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for AbbVie and, following the acquisition, if completed, the combined group. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that the divestitures and/or the pending acquisition will not be pursued, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other conditions to the pending acquisition, adverse effects on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares and on AbbVie’s or Allergan’s operating results because of a failure to complete the pending acquisition, failure to realize the expected benefits of the pending acquisition, failure to promptly and effectively integrate Allergan’s businesses, negative effects relating to the announcement of the pending acquisition or any further announcements relating to the pending acquisition or the consummation of the pending acquisition on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the pending acquisition, general economic and business conditions that affect the combined companies following the consummation of the pending acquisition, changes in global, political, economic, business, competitive, market and

regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals and competitive developments. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie’s or, as the case may be, Allergan’s experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this report could cause AbbVie’s plans with respect to Allergan or AbbVie’s or Allergan’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this report are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this report. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie or Allergan is set forth in AbbVie’s and Allergan’s periodic public filings with the U.S. Securities and Exchange Commission, including, but not limited to, AbbVie’s and Allergan’s Annual Report on Form 10-K for the year ended December 31, 2018, Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019, Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019, Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 and, from time to time, AbbVie’s and Allergan’s other investor communications, in each case, the contents of which are not incorporated by reference into, nor do they form part of, this report.

Any forward-looking statements in this report are based upon information available to AbbVie, Allergan and/or their respective board of directors, as the case may be, as of the date of this report and, while believed to be true when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, none of AbbVie, Allergan or any member of their respective board of directors undertakes any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to AbbVie, Allergan or their respective board of directors or any person acting on behalf of any of them are expressly qualified in their entirety by this paragraph.

Statement Required by the Irish Takeover Rules

The Allergan directors accept responsibility for the information contained in this report. To the best of the knowledge and belief of the Allergan directors (who have taken all reasonable care to ensure such is the case), the information contained in this report for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Allergan plc

     

By:

 

/s/ A. Robert D. Bailey

Name:

 

A. Robert D. Bailey

Title:

 

EVP and Chief Legal Officer and Corporate Secretary

Dated: January 27, 2020

EX-99.1 2 d875269dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

PRESS RELEASE

AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

Agreements Contingent on FTC and European Commission Approval and Completion of AbbVie’s Pending Acquisition of Allergan

NORTH CHICAGO, Ill. and DUBLIN, Jan. 27, 2020 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). These agreements are in conjunction with the ongoing regulatory approval process for AbbVie’s acquisition of Allergan.

AstraZeneca (NYSE: AZN) will acquire brazikumab, an investigational IL-23 inhibitor in Phase 2b/3 development for Crohn’s Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

Nestle (Swiss: NESN) will acquire and take full operational ownership of Zenpep upon closing the transaction with customary transition support from Allergan. Zenpep is a treatment, which is available in the United States, for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. Nestle also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.

“These definitive agreements represent significant progress toward the completion of our acquisition of Allergan,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “The new combined organization will be well positioned to deliver on our mission to patients with a broad portfolio of innovative therapies.”

“Today, we move another step closer to completing AbbVie’s acquisition of Allergan. Allergan’s commercial and R&D teams have invested so much of themselves into the development of brazikumab and the commercialization of Zenpep, and these divestiture agreements will enable that work to continue following the close of our planned acquisition,” said Brent Saunders, chairman and chief executive officer of Allergan.

 

AbbVie Inc.    +1 (847) 938-9190
1 North Waukegan Road    abbvie.com
North Chicago, IL 60064   

LOGO

 

The closings of the acquisitions of brazikumab and Zenpep are contingent upon receipt of U.S. Federal Trade Commission and European Commission approval, closing of AbbVie’s pending acquisition of Allergan and the satisfaction of other customary closing conditions.

On January 10, 2020, AbbVie and Allergan received conditional approval of the transaction by the European Commission, subject to the approved divestiture of brazikumab and other conditions.

AbbVie and Allergan continue to expect a first-quarter 2020 close of their pending transaction, subject to receipt of required regulatory approvals and other closing conditions.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers, and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com.

 

AbbVie Inc.    +1 (847) 938-9190
1 North Waukegan Road    abbvie.com
North Chicago, IL 60064   

LOGO

 

About Zenpep

ZENPEP® (pancrelipase) is a prescription medication for people who cannot digest food normally because their pancreas does not make enough enzymes. ZENPEP may help your body use fats, proteins, and sugars from food. ZENPEP contains a mixture of digestive enzymes (lipases, proteases, and amylases) from pig pancreas. In clinical studies, individuals with exocrine pancreatic insufficiency associated with cystic fibrosis absorbed more fat from foods than those treated with a placebo.

About Brazikumab

Brazikumab is a monoclonal antibody that binds to the IL23 receptor and is in development for Crohn’s Disease and Ulcerative Colitis with a companion biomarker. Brazikumab selectively blocks the IL23 immune signal, preventing intestinal inflammation. The Phase IIb/III INTREPID program is underway to assess brazikumab compared to placebo or adalimumab in Crohn’s Disease. The Phase II EXPEDITION trial is underway to assess brazikumab compared to placebo or vedolizumab in Ulcerative Colitis.

Forward-Looking Statements

This announcement contains certain forward-looking statements, including with respect to the pending acquisition involving AbbVie and Allergan, Allergan’s divestitures of brazikumab and Zenpep and AbbVie’s, Allergan’s and/or the combined group’s estimated or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for AbbVie and, following the acquisition, if completed, the combined group. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that the divestitures and/or the pending acquisition will not be pursued, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other conditions to the pending acquisition, adverse effects on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares and on AbbVie’s or Allergan’s operating results because of a failure to complete the pending acquisition, failure to realize the expected benefits of the pending acquisition, failure to promptly and effectively integrate Allergan’s businesses, negative effects relating to the announcement of the pending acquisition or any further announcements relating to the pending acquisition or the consummation of the pending acquisition on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares, significant transaction costs and/or

 

AbbVie Inc.    +1 (847) 938-9190
1 North Waukegan Road    abbvie.com
North Chicago, IL 60064   

LOGO

 

unknown or inestimable liabilities, potential litigation associated with the pending acquisition, general economic and business conditions that affect the combined companies following the consummation of the pending acquisition, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals and competitive developments. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie’s or, as the case may be, Allergan’s experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this announcement could cause AbbVie’s plans with respect to Allergan or AbbVie’s or Allergan’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this announcement are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this announcement. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie or Allergan is set forth in AbbVie’s and Allergan’s periodic public filings with the U.S. Securities and Exchange Commission, including, but not limited to, AbbVie’s and Allergan’s Annual Report on Form 10-K for the year ended December 31, 2018, Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019, Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019, Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 and, from time to time, AbbVie’s and Allergan’s other investor communications, in each case, the contents of which are not incorporated by reference into, nor do they form part of, this announcement.

Any forward-looking statements in this announcement are based upon information available to AbbVie, Allergan and/or their respective board of directors, as the case may be, as of the date of this announcement and, while believed to be true when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, none of AbbVie, Allergan or any member of their respective board of directors undertakes any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking

 

AbbVie Inc.    +1 (847) 938-9190
1 North Waukegan Road    abbvie.com
North Chicago, IL 60064   

LOGO

 

statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to AbbVie, Allergan or their respective board of directors or any person acting on behalf of any of them are expressly qualified in their entirety by this paragraph.

Statement Required by Irish Takeover Rules

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

The Allergan directors accept responsibility for the information contained in this report. To the best of the knowledge and belief of the Allergan directors (who have taken all reasonable care to ensure such is the case), the information contained in this report for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of Allergan plc or AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

###

 

Media:

Adelle Infante

(847) 938-8745

   

Investors:

Liz Shea

(847) 935-2211

 

AbbVie Inc.    +1 (847) 938-9190
1 North Waukegan Road    abbvie.com
North Chicago, IL 60064   
EX-101.SCH 3 agn-20200127.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 agn-20200127_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 agn-20200127_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Floating Rate Notes Due 2020 [Member] Floating Rate Notes Due 2020 [Member] M 0.500 Notes Due 2021 [Member] M 0.500 Notes Due 2021 [Member] M 1.500 Notes Due 2023 [Member] M 1.500 Notes Due 2023 [Member] M 1.250 Notes Due 2024 [Member] M 1.250 Notes Due 2024 [Member] M 2.625 Notes Due 2028 [Member] M 2.625 Notes Due 2028 [Member] M 2.125 Notes Due 2029 [Member] M 2.125 Notes Due 2029 [Member] EX-101.PRE 6 agn-20200127_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g875269img07.jpg GRAPHIC begin 644 g875269img07.jpg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ilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 8 95 1 false 7 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d875269d8k.htm agn-20200127.xsd agn-20200127_def.xml agn-20200127_lab.xml agn-20200127_pre.xml d875269dex991.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 10 0001193125-20-014823-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-014823-xbrl.zip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end XML 11 d875269d8k_htm.xml IDEA: XBRL DOCUMENT 0001578845 2020-01-27 2020-01-27 0001578845 us-gaap:CommonStockMember 2020-01-27 2020-01-27 0001578845 agn:FloatingRateNotesDue2020Member 2020-01-27 2020-01-27 0001578845 agn:M0.500NotesDue2021Member 2020-01-27 2020-01-27 0001578845 agn:M1.500NotesDue2023Member 2020-01-27 2020-01-27 0001578845 agn:M1.250NotesDue2024Member 2020-01-27 2020-01-27 0001578845 agn:M2.625NotesDue2028Member 2020-01-27 2020-01-27 0001578845 agn:M2.125NotesDue2029Member 2020-01-27 2020-01-27 false 0001578845 8-K 2020-01-27 ALLERGAN PLC L2 001-36867 98-1114402 Clonshaugh Business and Technology Park Coolock Dublin D17 E400 IE (862) 261-7000 false false false false false Ordinary Share, par value $0.0001 per share AGN NYSE Floating rate notes due 2020 AGN20A NYSE 0.500% notes due 2021 AGN21 NYSE 1.500% notes due 2023 AGN23A NYSE 1.250% notes due 2024 AGN24A NYSE 2.625% notes due 2028 AGN28 NYSE 2.125% notes due 2029 AGN29 NYSE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !A .U ?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ &$ [4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " 80#M0U9W!F.X K @ $0 &1O8U!R;W!S+V-O M&ULS9)12\,P$,>_BN2]O;05E=#E9<,G!<&!XEM(;EM8DX;DI-VW-ZU; MA^@'\#%W__SN=W"M#D+W$5]B'S"2Q70SNLXGH<.*'8B" $CZ@$ZE,B=\;N[Z MZ!3E9]Q#4/JH]@@UYW?@D)11I& "%F$A,MD:+71$17T\XXU>\.$S=C/,:, . M'7I*4)45,#E-#*>Q:^$*F&"$T:7O IJ%.%?_Q,X=8.?DF.R2&H:A')HYEW>H MX/WYZ75>M[ ^D?(:\Z]D!9T"KMAE\ENSWFP?F:QYS0M>%?7]EC\(SD5S^S&Y M_O"["KO>V)W]Q\870=G"K[N07U!+ P04 " 80#M0F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( !A .U!62?NTOP, +H6 8 >&PO=V]R:W-H965T&ULC9CO;MHP%,5?)Z)FGM M9I%^%/ODPDMYCY:IN?$U6A\Z[^M*E'TI=O)W?RV9\/YT_T>92A@OD MI4#^+]#C7,Y&X\@_%;Y8SEMW2MKSS=\70\;B7O;W9C5<'&_%^%D_^*Z_>EQ. MYMEQ:'-1/)P5\D8AKHJL[WTUD-! CN7JIESB<@7+U5BN;\I5,#ZJT-A 0P-- MRDU@0!4Y-C#0P)#R:6! %7?8((<&.2F?!094(2;880H=IK1>!!9 PN1\!RWN M:'T8-) P2<^@Q8S6AU$#"9.UF&"<)K1#&#?2,($+!EI!.X29 XUD0A>87"%I MAS!VI&%R%QAP0?F58?)(PT0O,.6"0BS#\)&&2Q^C+BC)DJ0/-%SZF'=!<98D M?:I17/J8>4&)5B1]H.'2Q]@+"K4BZ5,-%SX&7U"LE0Y-J(8QD9A\2:E6X3<, M:#@3#+ZD4*L\-*$:SH3YQ:9,J_!;##2<"<9>@A]V!@.)D98Z]LE"8EHE)5&% M' &-9CB2F%9)2=0A1TC#S073*BF).N0(:;C0,*T2D&B8#AA%.8M^',28*8!9 M&!K0:&8A5Y@S!1@*0T.:*>."05, (O)T"S1,:(IY@@8/R QI"I.FHDE3F#05 M01K0Z!GC@DE3$:0!C6%X5I@T%4$:TG"A8=(4)0!C1&,2Z8-!U!&M)P_R0Q:9J29K@.S)_1:-(T)DU'D 8TAEG%-29- M1Y &-(99A#4F34>0AC3<+<>D:4 :LXQK3)J.)LU@TDP$:4!CF%7<8-),!&E M8YA%V 1I2,.$9C!IAI*6,\NXP:29:-(,LZT301K0Y,PJ;C!I)H(TH,FY MN6#23 1I2!.&EMWL.@Z[NM^+=ELV7?+BO'?UN,VX<<[;OM_D0W]O=K987T\J MN_'#X;0_;L^[J><3[_:7G>+LNEV]_ =02P,$% @ &$ [4,<;%Q3L @ M"@D !0 !X;"]S:&%R9613=')I;F=S+GAM;)6676_:,!2&K[M?<80V:9,* M<<)7.E$DQD?%"A05I&FK=F$2DUA+[,QV5OCWLP/MUCCIM#MBG_,^KX^/CQA( MJ>"0)DQ>-V*ELH^.(X.8I%BV>$:8WMESD6*E/T7DR$P0',J8$)4FCH=0STDQ M90W(&?V9DS'/F;IN]-J-X4#2X4 -)SS(4\(48!;"E"FJCC!G)TG*V_! ]YJ+SYK#6JU(*'!64$YHJD\GLY=Z03PR)YEN"HO+O'B23E MQ3-AK),$3C0I) >X)<=R'$+([?9]O].M-;P]9I:\W[RMC5\30;DY8P@3K*S4 MIRJ]N;BHJM/9^#V)J-36M=X*IY;(:+&8WM^,5K!>C&L4YBS@(N/B5-Z-TE:@ MN&*AR\)#2W+AU0C-:$)@E:<[(NSJN%[FEP,E(M=.4W M7=?M=%"=B5$8"B+EY=,/*-KECEG'&">\#U;G\$ [7,>"/ZK8R&28664UZL6CTRT"#TMB:F)-M0T)ZB;$@EY!A ;]PDA-XBUIF=T2J?,*20>72)TJ4J>"Y+5Z7O:%ID>U)/"GE1FT)C3$V5%UAB](WN]*Z32=.7D&?PF1Q3Y/UBML'9^2])[N M$^;!%RF-J\%M91*Z0D4FH0ERG&B[,**Q+ 01C?)&+7AK-)\UK#,6P]-6(.5+ M.,*OS17WV)"8\[$.QT""BM7TJU[,>%S1"?Q'MLA]H+V_B998<3'X8?"KT;/_ M;3 (SPX:,<[^V&SU/3NW5D[OI6BU@KB6WQ9,;BQ89'RM0SKCQ*OG"S>E\@ X M2B[@4%1'Y+OC]@PCKK=I;&[5G/Z'FO_V/K>@P7%Y%.VO_K^\RW^BF"W=>&%S.F7\/#*JS[9^]33(R_] W[%[^?6T/!!XG-8 M\1S,Z6Y_"B]-\K!EG3>*G.[V9ZC%H-[.!?>_1/$#4$L#!!0 ( !A .U 6 M;2-_0P$ #P" / >&PO=V]R:V)O;VLN>&ULC5'+;L(P$/P5RQ_0!-0B M%1$NI0^DJD6EXNXD&[+"C\C>0,O7=^THA=YZLG=V/#L[7IRN \N=QGFCB$N_ST+G0=6A!2"CLVF>SS*CT,KE8M3:^.RZ M< 05H;,,1F"'< J7?BR%8L(1/E59R%P*U9-[0DW@5XK@V;N^0[LOY$2*!GV@ M;9R=F 8M&CQ#G:K0NM.+\WAVEI3>5MYIG5[%1GK$$\(OL@-/6/TADBH_%'LM MY"QGP2,&+%$C?1MZV(LXL8M9X>?(#;^N)\GXZ+:& M!BW4;SP@,,XA5!LOXI%TIK=WDWL.N]?Z@;%W^^I4TH\:X\ *A0V$LZ&8O:3RKC>LG^Z&JPLFAEC1"' MX17FP?+)K=$U'AZS@>S'G10R/'1Y?,5'W])=9SUZ" M,*V'O\E$_37 ZM=E7U!+ P04 " 80#M0"X_8 R$! !7! $P %M# M;VYT96YT7U1Y<&5S72YX;6RU5$U/PS ,_2M3KVC-X, !;;L 5Y@$?R D;ALU M7[*]T?U[W&Y#8BIB:-LEB?/L]UX2*_/W;0::=,%'6A0-B MVD1[1#K=$Y8(?LBAQF6ZD81B\MP)"\G>HA"4"G6"PG%A'TO=ZP80G85_64M5 MY0S89-9!2DK*"-I2 \#!E]1H!/O&Z&*]][O2R"\Z"+'JO/J14%[/!V\]C!L8 MD$LJL[0%C$D-P&Z\/4OPT TF(4PS"HKL1HXGEE:"DNH3+WE$Z%O'@CU)7*BO M]["?"=MA/7;AWR"I83KOUO]H=)G+H%W\S&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( !A .U!62?NTOP, +H6 8 M " ?<( !X;"]W;W)K&PO&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 80#M0"X_8 M R$! !7! $P @ %Q% 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 "@ * ( " ##%0 ! end JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d875269d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 8, "dts": { "definitionLink": { "local": [ "agn-20200127_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "d875269d8k.htm" ] }, "labelLink": { "local": [ "agn-20200127_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "agn-20200127_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "agn-20200127.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 6, "memberStandard": 1, "nsprefix": "agn", "nsuri": "http://www.allergan.com/20200127", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d875269d8k.htm", "contextRef": "duration_2020-01-27_to_2020-01-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d875269d8k.htm", "contextRef": "duration_2020-01-27_to_2020-01-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 7, "tag": { "agn_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.allergan.com/20200127", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "agn_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.allergan.com/20200127", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "agn_FloatingRateNotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Floating Rate Notes Due 2020 [Member]", "terseLabel": "Floating Rate Notes Due 2020 [Member]" } } }, "localname": "FloatingRateNotesDue2020Member", "nsuri": "http://www.allergan.com/20200127", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_M0.500NotesDue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "M 0.500 Notes Due 2021 [Member]", "terseLabel": "M 0.500 Notes Due 2021 [Member]" } } }, "localname": "M0.500NotesDue2021Member", "nsuri": "http://www.allergan.com/20200127", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_M1.250NotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "M 1.250 Notes Due 2024 [Member]", "terseLabel": "M 1.250 Notes Due 2024 [Member]" } } }, "localname": "M1.250NotesDue2024Member", "nsuri": "http://www.allergan.com/20200127", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_M1.500NotesDue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "M 1.500 Notes Due 2023 [Member]", "terseLabel": "M 1.500 Notes Due 2023 [Member]" } } }, "localname": "M1.500NotesDue2023Member", "nsuri": "http://www.allergan.com/20200127", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_M2.125NotesDue2029Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "M 2.125 Notes Due 2029 [Member]", "terseLabel": "M 2.125 Notes Due 2029 [Member]" } } }, "localname": "M2.125NotesDue2029Member", "nsuri": "http://www.allergan.com/20200127", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_M2.625NotesDue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "M 2.625 Notes Due 2028 [Member]", "terseLabel": "M 2.625 Notes Due 2028 [Member]" } } }, "localname": "M2.625NotesDue2028Member", "nsuri": "http://www.allergan.com/20200127", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.allergan.com//20200127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 14 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information
Jan. 27, 2020
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001578845
Document Type 8-K
Document Period End Date Jan. 27, 2020
Entity Registrant Name ALLERGAN PLC
Entity Incorporation State Country Code L2
Entity File Number 001-36867
Entity Tax Identification Number 98-1114402
Entity Address, Address Line One Clonshaugh Business and Technology Park
Entity Address, Address Line Two Coolock
Entity Address, City or Town Dublin
Entity Address, Postal Zip Code D17 E400
Entity Address, Country IE
City Area Code (862)
Local Phone Number 261-7000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Ordinary Share, par value $0.0001 per share
Trading Symbol AGN
Security Exchange Name NYSE
Floating Rate Notes Due 2020 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Floating rate notes due 2020
Trading Symbol AGN20A
Security Exchange Name NYSE
M 0.500 Notes Due 2021 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 0.500% notes due 2021
Trading Symbol AGN21
Security Exchange Name NYSE
M 1.500 Notes Due 2023 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 1.500% notes due 2023
Trading Symbol AGN23A
Security Exchange Name NYSE
M 1.250 Notes Due 2024 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 1.250% notes due 2024
Trading Symbol AGN24A
Security Exchange Name NYSE
M 2.625 Notes Due 2028 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 2.625% notes due 2028
Trading Symbol AGN28
Security Exchange Name NYSE
M 2.125 Notes Due 2029 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 2.125% notes due 2029
Trading Symbol AGN29
Security Exchange Name NYSE
XML 16 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}